Addison's Disease Clinical Trial
Official title:
Glucocorticoid Treatment in Addison's Disease
Addison's disease is a rare condition which in most cases is caused by autoimmune
destruction of the adrenals, leading to deficiency of cortisol, aldosterone and adrenal
androgens. Unrecognized the disease is life threatening, but with proper treatment patients
can live near normal lives.
The conventional glucocorticoid replacement therapy renders the cortisol levels
unphysiological, which may cause symptoms and long-term complications. Glucocorticoid
replacement therapy is technically feasible by continuous subcutaneous hydrocortisone
infusion (CSHI), and can mimic the normal diurnal cortisol rhythm. This study aims to
further evaluate CSHI treatment in terms of metabolic effects, effects on health-related
quality-of-life and sleep in an 8 months randomised open label clinical trial with crossover
design.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00444119 -
Survey in Patients With Chronic Adrenal Insufficiency in Germany
|
N/A | |
| Completed |
NCT01452893 -
Counterregulatory Hormone Production in Adrenal Insufficiency and Diabetes Type I
|
N/A | |
| Recruiting |
NCT05350020 -
The Effects of Two Brands of Hydrocortisone Injected Intramuscularly Into Deltoid and Thigh Muscles
|
Phase 4 | |
| Not yet recruiting |
NCT01657123 -
Exercise Capacity and Recovery in Addison's Disease
|
N/A | |
| Not yet recruiting |
NCT04252001 -
Growing up With the Young Endocrine Support System (YESS!)
|
N/A | |
| Completed |
NCT00688987 -
The Hypothalamic-Pituitary-Adrenal (HPA) Axis as an Effector System in Weight Regulation
|
N/A | |
| Completed |
NCT00004313 -
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency
|
Phase 3 |